ClinicalTrials.gg
CompletedNCT03047395LIMMITLESSUpdated Dec 11, 2024Results posted

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

A Phase 3 interventional study of risankizumab in Psoriasis, sponsored by AbbVie. Completed at 233 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,170
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
Largest of 30
2,170 · median 162
Started
2017
with 2 others
Phase 3
17 of 30
none open now
Registered
11th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.

Read the detailed description

This is a Phase 3, single-arm, multicenter open label extension (OLE) study designed to investigate the long-term safety and efficacy of 150 mg risankizumab in the treatment of moderate to severe chronic plaque psoriasis. Approximately 2200 participants who meet the entry criteria are planned to be enrolled in this study, rolling over from the preceding Phase 2/3 studies.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a history of moderate to severe chronic plaque psoriasis, who have completed one of the preceding studies.
  • Participants must be candidates for prolonged open label risankizumab treatment according to investigator judgment.
  • Females of must have a negative urine pregnancy test result at Baseline.

If female, participant must be either , OR permanently surgically sterile OR for women of childbearing potential practicing at least one protocol specified method of , starting at Baseline through at least 20 weeks after the last dose of study drug.

  • Participants must have signed and dated a written in accordance with Good Clinical Practice (GCP) and local legislation prior to admission into the study.

Exclusion criteria

Exclusion Criteria:

  • Premature discontinuation for any reason in the preceding study.
  • Participants who have developed guttate, erythrodermic, pustular or drug-induced psoriasis as diagnosed by the investigator during the preceding study.
  • Use of any prohibited medication or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
  • Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse) other than psoriasis, surgical procedure (i.e., organ transplant), medical examination finding (including vital signs and ), or laboratory value outside the reference range that in the opinion of the investigator is and would make the study participant unreliable to adhere to the protocol or to complete the study, compromise the safety of the subject, or compromise the quality of the data.
  • Previous enrollment in this study.
  • Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or within 20 weeks after the last dose of study drug.
  • Time elapsed is > 8 weeks since the completion visit in the preceding study.
  • Participant is considered by the investigator for any reason, to be an unsuitable candidate for the study and not able to comply with the study protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,170 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Participants will receive risankizumab administered by subcutaneous injection.

    Biological: risankizumab

Interventions

  • Biologicalrisankizumab

    Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.

    Also known as: ABBV-066, Skyrizi, BI 655066

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events and Non-Serious Adverse Events

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Median follow-up time of 1905 days

07

Results

Posted Dec 11, 2024

Participant flow

Participants from Studies M16-008 (NCT02684370), M16-010 (NCT02694523), M15-995 (NCT02684357), M16-178 (NCT03255382), M16-009 (NCT02203851), M15-992 (NCT02672852), and M16-004 (NCT03000075) entered this open-label extension (OLE) study from 232 sites across 17 countries (Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Japan, Mexico, Poland, Portugal, Republic of Korea, Spain, Sweden, Taiwan, and US).

Participant flow — Overall Study
MilestoneRisankizumab 150 mg
Started2170
Completed1601
Not completed569
Withdrew: Adverse event142
Withdrew: Withdrawal by subject155
Withdrew: Lost to follow-up144
Withdrew: Covid-19 infection2
Withdrew: Covid-19 logistical restrictions9
Withdrew: Other, not specified117

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events and Non-Serious Adverse Events

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame:
Median follow-up time of 1905 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events and Non-Serious Adverse Events
ParticipantsRisankizumab 150 mg
Serious Adverse Events435
Non-serious Adverse Events1215

Adverse events

Collected over Median follow-up time of 1905 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab 150 mg28/2,170 (1.3%)435/2,170 (20%)1,215/2,170 (56%)
Most frequent serious events
Showing 10 of 389
Most frequent serious events
EventRisankizumab 150 mg
OSTEOARTHRITISMusculoskeletal and connective tissue disorders17/2170
ACUTE MYOCARDIAL INFARCTIONCardiac disorders13/2170
COVID-19Infections and infestations13/2170
ATRIAL FIBRILLATIONCardiac disorders9/2170
CORONARY ARTERY DISEASECardiac disorders9/2170
MYOCARDIAL INFARCTIONCardiac disorders9/2170
NEPHROLITHIASISRenal and urinary disorders8/2170
COVID-19 PNEUMONIAInfections and infestations7/2170
PNEUMONIAInfections and infestations7/2170
SYNCOPENervous system disorders7/2170
Most frequent other events
Most frequent other events
EventRisankizumab 150 mg
NASOPHARYNGITISInfections and infestations480/2170
COVID-19Infections and infestations360/2170
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations312/2170
HYPERTENSIONVascular disorders227/2170
ARTHRALGIAMusculoskeletal and connective tissue disorders217/2170
HEADACHENervous system disorders134/2170
BACK PAINMusculoskeletal and connective tissue disorders124/2170

Baseline characteristics

Age, Customized
Age, Customized(Participants)Risankizumab 150 mg
< 40 years658
40 - < 65 years1264
>= 65 years248
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab 150 mg
Female634
Male1536
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risankizumab 150 mg
Hispanic or Latino257
Not Hispanic or Latino1913
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risankizumab 150 mg
American Indian or Alaska Native15
Asian466
Native Hawaiian or Other Pacific Islander9
Black or African American50
White1622
More than one race8
Unknown or Not Reported0
08

Study locations

233 sites
  • Total Skin and Beauty Dermatology Center /ID# 154000
    Birmingham, Alabama 35205, United States
  • University of Alabama at Birmingham - Main /ID# 153983
    Birmingham, Alabama 35233, United States
  • NW Arkansas Clinical Trials Center /ID# 154014
    Rogers, Arkansas 72758, United States
  • Bakersfield Derma & Skin Cance /ID# 154008
    Bakersfield, California 93309, United States
  • California Dermatology and Research Institute /ID# 154007
    Encinitas, California 92024, United States
  • T. Joseph Raoof, MD, Inc. /ID# 154078
    Encino, California 91436, United States
  • Center for Dermatology Clinical Research /ID# 154009
    Fremont, California 94538, United States
  • Kaiser Permanente Los Angeles /ID# 154079
    Los Angeles, California 90027, United States
  • Dermatology Research Associates /ID# 153977
    Los Angeles, California 90045, United States
  • Wallace Medical Group /ID# 154025
    Los Angeles, California 90056, United States
  • Dermatology Specialists, Inc /ID# 153984
    Oceanside, California 92056, United States
  • Huntington Medical Foundation /ID# 154002
    Pasadena, California 91105, United States
  • Medderm Associates /ID# 154098
    San Diego, California 92103, United States
  • Southern California Dermatology /ID# 154006
    Santa Ana, California 92701, United States
  • UNISON Center for Clinical Tri /ID# 153979
    Sherman Oaks, California 91403, United States
  • New England Research Associates, LLC /ID# 154004
    Bridgeport, Connecticut 06606-1827, United States
  • UConn Health /ID# 154128
    Farmington, Connecticut 06030, United States
  • Florida Academic Centers Research /ID# 154045
    Coral Gables, Florida 33134, United States
  • Leavitt Medical Associates of Florida /ID# 154046
    Ormond Beach, Florida 32174, United States
  • Progressive Medical Research /ID# 154027
    Port Orange, Florida 32127, United States
  • Hamilton Research, LLC /ID# 153980
    Alpharetta, Georgia 30022, United States
  • Advanced Medical Research, PC /ID# 153999
    Sandy Springs, Georgia 30328-6141, United States
  • Northwestern University Feinberg School of Medicine /ID# 153974
    Chicago, Illinois 60611-2927, United States
  • Rush University Medical Center /ID# 154099
    Chicago, Illinois 60612, United States
  • Arlington Dermatology /ID# 153975
    Rolling Meadows, Illinois 60008, United States
  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 154011
    Skokie, Illinois 60077, United States
  • Dundee Dermatology /ID# 154110
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin, LLC /ID# 154146
    Indianapolis, Indiana 46256, United States
  • The Dermatology Center PSC - New Albany /ID# 154075
    New Albany, Indiana 47150, United States
  • The Indiana Clinical Trials Center /ID# 153976
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic Center /ID# 154147
    South Bend, Indiana 46617, United States
  • Epiphany Dermatology of Kansas LLC /ID# 153993
    Overland Park, Kansas 66210, United States
  • Skin Sciences, PLLC /ID# 153991
    Louisville, Kentucky 40217, United States
  • DS Research /ID# 154028
    Louisville, Kentucky 40241, United States
  • Massachusetts General Hospital /ID# 153990
    Boston, Massachusetts 02114, United States
  • ActivMed Practices and Research, LLC. /ID# 154044
    Methuen, Massachusetts 01844, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 154111
    Ann Arbor, Michigan 48109, United States
  • Great Lakes Research Group - Bay City /ID# 153998
    Bay City, Michigan 48706, United States
  • Michigan Center for Skin Care Research /ID# 153986
    Clinton Township, Michigan 48038, United States
  • Somerset Skin Centre /ID# 154097
    Troy, Michigan 48084, United States
  • Minnesota Clinical Study Center /ID# 154015
    New Brighton, Minnesota 55112, United States
  • Central Dermatology, PC /ID# 154013
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, PC /ID# 154024
    Omaha, Nebraska 68144, United States
  • Dartmouth-Hitchcock Medical Center /ID# 154095
    Lebanon, New Hampshire 03756, United States
  • Psoriasis Treatment Center of Central New Jersey /ID# 154001
    East Windsor, New Jersey 08520, United States
  • Schweiger Dermatology Group /ID# 202489
    Verona, New Jersey 07044, United States
  • Forest Hills Dermatology Group /ID# 154113
    Kew Gardens, New York 11415, United States
  • Icahn School of Medicine at Mount Sinai /ID# 154129
    New York, New York 10029, United States
  • The Rockefeller University /ID# 153994
    New York, New York 10065, United States
  • DermResearchCenter of New York, Inc. /ID# 154012
    Stony Brook, New York 11790, United States
  • Buffalo Medical Group /ID# 154148
    Williamsville, New York 14221, United States
  • Darst Dermatology /ID# 154076
    Charlotte, North Carolina 28277, United States
  • Dermatology Consulting Service /ID# 154010
    High Point, North Carolina 27262, United States
  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 202490
    Raleigh, North Carolina 27612, United States
  • Wilmington Dermatology Center /ID# 154109
    Wilmington, North Carolina 28403, United States
  • Synexus Research Cincinnati /ID# 153997
    Cincinnati, Ohio 45236, United States
  • Oregon Dermatology and Research Center /ID# 153982
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center /ID# 154003
    Portland, Oregon 97223, United States
  • Altoona Ctr Clinical Res /ID# 153981
    Duncansville, Pennsylvania 16635, United States
  • Paddington Testing Co., Inc. /ID# 154022
    Philadelphia, Pennsylvania 19103, United States
  • University of Pittsburgh MC /ID# 153995
    Pittsburgh, Pennsylvania 15260, United States
  • Clinical Partners, LLC /ID# 154096
    Johnston, Rhode Island 02919, United States
  • Coastal Clinical Research Center of the Carolinas /ID# 154112
    Charleston, South Carolina 29414, United States
  • Synexus Clinical Research US, Inc. /ID# 154127
    Greer, South Carolina 29651-1123, United States
  • Coastal Carolina Research Center /ID# 153992
    North Charleston, South Carolina 29405, United States
  • Health Concepts /ID# 153996
    Rapid City, South Dakota 57702, United States
  • Austin Dermatology Associates /ID# 154042
    Austin, Texas 78705, United States
  • Bellaire Dermatology Associates /ID# 153987
    Bellaire, Texas 77401, United States
  • Modern Research Associates, PLLC /ID# 154043
    Dallas, Texas 75231, United States
  • Menter Dermatology Res Inst /ID# 153985
    Dallas, Texas 75246, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 154005
    Houston, Texas 77004-8097, United States
  • Suzanne Bruce and Associates-Houston /ID# 154026
    Houston, Texas 77056, United States
  • Derm Clin Res Ctr San Antonio /ID# 153978
    San Antonio, Texas 78229, United States
  • Progressive Clinical Research /ID# 154149
    San Antonio, Texas 78229, United States
  • Dermatology San Antonio /ID# 154077
    San Antonio, Texas 78249, United States
  • Center for Clinical Studies Webster TX /ID# 154150
    Webster, Texas 77598, United States
  • Virginia Clinical Research, Inc. /ID# 154016
    Norfolk, Virginia 23502, United States
  • Dermatology Associates of Seattle /ID# 153988
    Seattle, Washington 98101, United States
  • Premier Clinical Research /ID# 154284
    Spokane, Washington 99202, United States
  • Paratus Clinical Research Woden /ID# 154307
    Phillip, Australian Capital Territory 2606, Australia
  • St George Dermatology & Skin Cancer Centre /ID# 154308
    Kogarah, New South Wales 2217, Australia
  • Specialist Connect Pty Ltd /ID# 154311
    Woolloongabba, Queensland 4102, Australia
  • North Eastern Health Specialists /ID# 154309
    Campbelltown, South Australia 5074, Australia
  • Skin Health Institute Inc /ID# 154305
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology - Melbourne /ID# 154310
    Melbourne, Victoria 3995, Australia
  • Fremantle Dermatology /ID# 154306
    Fremantle, Western Australia 6160, Australia
  • Landeskrankenhaus Feldkirch /ID# 154303
    Feldkirch, Vorarlberg 6800, Austria
  • Klinik Landstrasse /ID# 154300
    Vienna, Wien 1030, Austria
  • Medizinische Universitaet Wien /ID# 154302
    Vienna, Wien 1090, Austria
  • Cliniques Universitaires de Bruxelles Hopital Erasme /ID# 154293
    Brussels, Bruxelles-Capitale 1070, Belgium
  • Universitair Ziekenhuis Brussel /ID# 154295
    Jette, Bruxelles-Capitale 1090, Belgium
  • Cliniques Universitaires UCL Saint-Luc /ID# 154294
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • CHU de Liege Sart Tilman /ID# 154297
    Liège, Liege 4000, Belgium
  • UZ Gent /ID# 154296
    Gent, Oost-Vlaanderen 9000, Belgium
  • IMTR - Grand Hopital de Charleroi /ID# 154298
    Loverval, 6280, Belgium
  • Kirk Barber Research, CA /ID# 153840
    Calgary, Alberta T2G 1B1, Canada
  • Dermatology Research Institute Inc. /ID# 153850
    Calgary, Alberta T2J 7E1, Canada
  • Stratica Medical /ID# 153848
    Edmonton, Alberta T5K 1X3, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 153842
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research /ID# 153851
    Surrey, British Columbia V3V 0C6, Canada

Showing the first 100 of 233 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021 Dec;185(6):1135-1145. doi: 10.1111/bjd.20595. Epub 2021 Sep 21. PubMed 34157132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2023, 81 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 81 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 9, 2017
StartActual
Feb 27, 2017
Primary completionActual
Nov 29, 2023
CompletionActual
Nov 29, 2023
Results first posted
Dec 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03047395
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Feb 27, 2017
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion